Trendlyne Blog: , Latest on stock market and finance in India and the world.

20 Aug 2025

1106.00

1.38%

Aurobindo Pharma leads $5 billion race to acquire Prague-based Zentiva

Business Standard

Shortly after reports of the potential acquisition surfaced, Aurobindo clarified that no binding agreement or definitive decision has been made regarding the deal

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Natco Pharma Ltd.

20 Aug 2025

850.00

-0.49%

Natco Pharma introduces generic Bosentan in US for pulmonary arterial hypertension treatment

Business Line

Natco received USFDA approval for its ANDA and secured the coveted first-to-file status, granting it 180-day generic drug exclusivity

Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

19 Aug 2025

2036.00

0.86%

'Buy' Glenmark Pharma Shares Maintains Motilal Oswal Despite Weak Q1 Results Check Target Price

NDTV Profit

Motilal Oswal maintain 'Buy' rating on Glenmark Pharma and hikes target price sees strategic transformation to be underway

Glenmark Pharmaceuticals Ltd. is trading below its 50 day SMA of 2062.7

Glenmark Pharma Eyes 19-20% Ebitda Margin In FY26 Driven By Strong Performance Across Markets

NDTV Profit | 19 Aug 2025 1 more

Alembic Pharmaceuticals Ltd.

19 Aug 2025

926.00

0.63%

Alembic Pharma shares rise 2% on pulmonary hypertension drug approval

Business Standard

Alembic Pharma shares rose 2.3 per cent on Tuesday, after the company received US Food & Drug Administration (USFDA) final approval for its Abbreviated New Drug Application (ANDA) Macitentan Tablets

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Marksans Pharma Ltd.

18 Aug 2025

169.21

-0.51%

Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here

Business Standard

The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem in the UK, had received marketing authorisation for its products

Marksans Pharma Ltd. is trading below all available SMAs

Alembic Ltd.

18 Aug 2025

103.64

-0.53%

Alembic gets USFDA nod for generic drug for skin condition

Business Line

The company has received final approval from the US Food & Drug Administration for its abbreviated new drug application for Tretinoin Cream USP, the drug maker said in a statement

Alembic Ltd. has lost -26.71% in the last 1 Year

Alembic Pharmaceuticals Ltd.

18 Aug 2025

926.00

0.63%

Alembic gets USFDA's approval for generic acne drug Tretinoin Cream

Business Standard

Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication to treat acne vulgaris in the US market. The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP (0.025 per cent), the drug maker said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025 pr cent, of Bausch Health US, LLC, it added. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. According to IQVIA, Tretinoin cream USP, 0.025 per cent, has an estimated market size of USD 94 million for the twelve months ending June 2025. Shares of the company were trading 1.03 per cent up at Rs 968.10 apiece on BSE.

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Aurobindo Pharma Ltd.

17 Aug 2025

1106.00

1.38%

Aurobindo Pharma expects China plant to break even at EBITDA level this year

Business Line

"This facility with an initial capacity of 2 bn units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA level by Q3 FY26"